Friday, June 29, 2018

Lenabasum shows promise for diffuse cutaneous systemic sclerosis

The selective cannabinoid receptor type 2 agonist lenabasum exhibited an acceptable safety profile while improving outcomes in patients with diffuse cutaneous systemic sclerosis, according to results of a phase II study.

No comments:

Post a Comment